Vaxess Lands First Tranche of $4M Round

“Newly-launched Vaxess Technologies Inc., a life sciences company developing vaccine stabilization technology, has closed the first tranche of a $3.75 million Series A round of financing.

Norwich Ventures led the $1.25 million round, which also included participation from angel investor Jeffrey C. Walker, Co-founder Michael Schrader told Mass High Tech. The Boston-based company will use the funds to advance the development of its silk-stabilized products through pre-clinical development and to continue its collaboration with pharmaceutical companies and other partners…”

Boston Business Journal